Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management.

Literature DB >> 31857955

Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management.

Yayi He¹, Caicun Zhou¹.

Abstract

Entities: Disease

Year: 2019 PMID： 31857955 PMCID： PMC6894986 DOI： 10.21037/tlcr.2019.05.02

Source DB: PubMed Journal: Transl Lung Cancer Res ISSN： 2218-6751

× No keyword cloud information.

27 in total

1. Cancer statistics, 2018.

Authors: Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal: CA Cancer J Clin Date: 2018-01-04 Impact factor: 508.702

Review 2. Understanding, recognizing, and managing toxicities of targeted anticancer therapies.

Authors: Grace K Dy; Alex A Adjei
Journal: CA Cancer J Clin Date: 2013-05-28 Impact factor: 508.702

3. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.

Authors: Kosuke Kashiwabara; Hiroshi Semba; Shinji Fujii; Shinsuke Tsumura
Journal: Cancer Chemother Pharmacol Date: 2017-03-03 Impact factor: 3.333

4. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.

Authors: Seiji Niho; Koichi Goto; Kiyotaka Yoh; Young Hak Kim; Hironobu Ohmatsu; Kaoru Kubota; Nagahiro Saijo; Yutaka Nishiwaki
Journal: Jpn J Clin Oncol Date: 2006-05-15 Impact factor: 3.019

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Authors: Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; Shucai Zhang; Jie Wang; Songwen Zhou; Shengxiang Ren; Shun Lu; Li Zhang; Chengping Hu; Chunhong Hu; Yi Luo; Lei Chen; Ming Ye; Jianan Huang; Xiuyi Zhi; Yiping Zhang; Qingyu Xiu; Jun Ma; Li Zhang; Changxuan You
Journal: Lancet Oncol Date: 2011-07-23 Impact factor: 41.316

6. Severe acute interstitial pneumonia and gefitinib.

Authors: Akira Inoue; Yasuo Saijo; Makoto Maemondo; Kazunori Gomi; Yutaka Tokue; Yuichiro Kimura; Masahito Ebina; Toshiaki Kikuchi; Takuya Moriya; Toshihiro Nukiwa
Journal: Lancet Date: 2003-01-11 Impact factor: 79.321

7. Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation.

Authors: Akira Inoue; Hong Xin; Takuji Suzuki; Masahiko Kanehira; Yoshio Kuroki; Tatsuro Fukuhara; Toshiaki Kikuchi; Makoto Maemondo; Toshihiro Nukiwa; Yasuo Saijo
Journal: Cancer Sci Date: 2008-08 Impact factor: 6.716

8. Erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitial lung disease.

Authors: Qing Tian; Liang-An Chen
Journal: Case Rep Oncol Date: 2011-09-16